How to Get a Dexcom CGM With or Without Insurance

Getting a Dexcom continuous glucose monitor involves navigating a patchwork of insurance rules, prescription requirements, and cost considerations that vary depending on your diabetes type, your treatment plan, and where you live. Most people with diabetes who use insulin can get a Dexcom CGM covered through insurance, but millions of others with type 2 diabetes face coverage denials even as the clinical evidence supporting broader access grows. The process looks different depending on whether you have private insurance, Medicare, Medicaid, or no coverage at all.

Private Insurance Coverage

Most commercial insurance plans cover Dexcom CGMs, but the criteria you need to meet depend on your specific plan. The common thread across insurers is a diagnosis of diabetes and a prescription from your doctor. Many plans require that you use insulin, whether through injections or a pump, and some want documentation showing that you check your blood sugar multiple times a day.

Your doctor’s office typically handles the prior authorization process, which involves submitting clinical notes showing your diagnosis, your current treatment regimen, and your blood sugar management history. Some plans approve CGM coverage without much friction, especially for people with type 1 diabetes or those on intensive insulin therapy. For people with type 2 diabetes who take oral medications or non-insulin injectables, the approval process can be more difficult.

Cost and insurance barriers are the single biggest reason people stop using CGMs after starting them. One study found that among people who discontinued CGM use after hospital discharge, three out of four cited cost or insurance problems, compared to about a third of those who continued using the device.¹ That gap highlights how even getting initial approval is only half the battle; sustaining coverage matters just as much.

The way your Dexcom supplies are fulfilled also affects what you pay. Some insurance plans route CGM supplies through a durable medical equipment provider, while others treat sensors as pharmacy benefits. Pharmacy channel fulfillment often means a copay similar to what you’d pay for a prescription medication, which can be significantly less than the DME route depending on your plan’s cost-sharing structure. When your doctor writes the prescription, ask whether it can be filled at a pharmacy rather than through a DME supplier, as this single choice can change your monthly out-of-pocket cost by a wide margin.

Medicare Requirements

Medicare covers Dexcom CGMs under its DME benefit, but the eligibility criteria are narrower than many private plans. To qualify, you generally need a diabetes diagnosis, a treatment plan that requires frequent blood sugar adjustments, and you must be using insulin or have a documented history of problematic blood sugar control. Medicare also requires that you see your prescribing provider in person at regular intervals to maintain coverage.

These restrictions have drawn criticism from researchers and clinicians who argue they exclude large groups of people who would benefit from CGM. Current eligibility criteria required by public and many private insurers are effectively “denying millions of individuals with T2D access to this valuable technology,” even as evidence grows that CGM helps people with type 2 diabetes who are not on intensive insulin therapy.²

Medicare Advantage plans, which are run by private insurers under contract with Medicare, sometimes have slightly different procedures for authorization but must cover at least what original Medicare covers. If you’re on a Medicare Advantage plan, check with your plan directly about how they handle CGM authorization, since the specific paperwork and preferred suppliers can differ.

Medicaid Coverage Varies Dramatically by State

Medicaid presents the most unpredictable landscape for CGM access. Although Medicaid is a federal program, there is no consistent national policy for CGM coverage across states.³ Each state sets its own rules, meaning a person who qualifies for a Dexcom CGM in one state might be flatly denied in another.

Some states cover CGMs for people with type 1 diabetes and those on intensive insulin therapy, broadly mirroring Medicare’s approach. Others have more restrictive criteria, and a handful have been expanding access in recent years as the evidence base has grown. If you’re on Medicaid and want a Dexcom CGM, your first step should be calling your state’s Medicaid program or asking your endocrinologist’s office what the current criteria are. These rules change, and what was true a year ago may no longer apply.

The inconsistency creates real disparities. People on Medicaid tend to have fewer resources to navigate bureaucratic hurdles or pay out of pocket if they’re denied, and the populations most likely to be on Medicaid are also those at highest risk for diabetes complications. This is not an abstract policy problem; it directly affects who gets access to a tool that can meaningfully improve blood sugar control.

Getting a Dexcom CGM Without Insurance

If you don’t have insurance or your plan won’t cover a Dexcom CGM, you have several options, though none of them are cheap on the traditional prescription path.

The first route is to get a prescription from your doctor for a Dexcom G7 and pay out of pocket. Without any insurance or discount programs, a month’s supply of Dexcom G7 sensors typically runs several hundred dollars. Prices vary depending on the supplier, and some online pharmacies or DME providers offer lower cash-pay rates than others, so shopping around is worthwhile. Dexcom also offers manufacturer savings programs for commercially insured patients that can reduce copays, and for people with no insurance at all, the company has offered patient assistance in certain situations. Eligibility and availability for these programs change, so checking Dexcom’s website directly is the most reliable approach.

The biggest development for uninsured or underinsured people has been the arrival of over-the-counter CGMs. Dexcom’s Stelo biosensor, cleared by the FDA, is available without a prescription for adults 18 and older who are not on insulin. It’s designed for people with type 2 diabetes or those who want to understand their glucose patterns and don’t meet the traditional criteria for a prescription CGM. The Stelo costs significantly less than the G7 on a monthly basis, making it the most accessible entry point for people paying entirely out of pocket. The tradeoff is that the Stelo lacks some features of the G7, including real-time urgent low glucose alerts, which is why it’s cleared for a non-insulin-using population where severe hypoglycemia risk is lower.

What to Do When Your Insurer Says No

Insurance denials for CGM are common, but they are not always the final word. Most plans have a formal appeals process, and your chances improve if you approach it systematically.

The first step is understanding why you were denied. The explanation of benefits or denial letter should state a reason, whether it’s that CGM is considered “not medically necessary” for your situation, that you don’t meet specific clinical criteria, or that documentation was incomplete. Incomplete documentation is the easiest to fix; your doctor’s office can resubmit with the missing information.

For denials based on medical necessity, the appeal needs to make a clinical case. Your doctor can write a letter of medical necessity explaining why CGM matters for your specific situation, ideally including your blood sugar history, any episodes of severe hypoglycemia or hyperglycemia, and how CGM data would change treatment decisions. Including published research can strengthen the case considerably, and the evidence base for CGM in broader populations has expanded in recent years. If the initial appeal fails, most states allow you to request an external review, where an independent reviewer evaluates whether the denial was appropriate. Some patients also have success involving their state insurance commissioner’s office.

Persistence matters here. The denial process is designed, intentionally or not, to discourage people from pursuing coverage. Many people who are initially denied end up getting approval on appeal, particularly when their provider submits detailed supporting documentation.

The Evidence That Coverage Rules Haven’t Caught Up With

One of the biggest frustrations for people trying to get a Dexcom CGM is that insurance criteria often require insulin use, while the clinical evidence increasingly shows that CGM benefits people with type 2 diabetes who aren’t on insulin at all. This evidence is relevant not just as background science but as practical ammunition for appeals and as context for why the coverage landscape is likely to shift.

A meta-analysis of randomized controlled trials looking at CGM in people with type 2 diabetes not on insulin found that CGM use was linked to a meaningful drop in HbA1c and a significant increase in time spent in the target blood sugar range.⁴ These weren’t marginal differences; participants wearing CGMs spent meaningfully more time with blood sugar in a healthy range and less time running high.

Individual trials have been even more striking. One clinical trial of people with type 2 diabetes not using insulin found that CGM use was associated with reduced average glucose, higher time in range, lower HbA1c, lower triglycerides, lower blood pressure, and a reduction in predicted ten-year cardiovascular risk.⁵ The improvements went well beyond blood sugar, suggesting that the behavioral feedback loop created by seeing real-time glucose data influences diet, activity, and medication adherence in ways that ripple across multiple health markers.

A large real-world study of adults with poorly controlled type 2 diabetes not using insulin showed that Dexcom CGM use was associated with an average increase in time in range of about 17 percentage points over 12 months, moving from roughly 42% to 59%.⁶ For context, time in range is the percentage of the day your blood sugar stays between 70 and 180 mg/dL, and jumping from 42% to 59% represents a substantial improvement in daily glucose control.

Another study focused on people with type 2 diabetes treated with less intensive therapies found a large drop in HbA1c at six months, with time in range climbing from about 57% to 72%.⁷ This body of research is what your doctor can cite in an appeal letter. It also informs the broader policy conversation: as more insurers and state Medicaid programs review their CGM criteria, these findings are driving expansions in coverage.

Gestational Diabetes and the Coverage Gap

Pregnant women with gestational diabetes face a particularly frustrating coverage landscape. Research has shown that CGM use reduces maternal and fetal complications in pregnant women with diabetes, yet most state Medicaid programs do not cover CGM for women with gestational diabetes specifically.⁸

This gap is especially consequential because gestational diabetes is a time-limited condition where tight blood sugar control matters enormously for both the mother and baby. The window for intervention is short, and the consequences of poor control, including higher rates of preeclampsia, cesarean delivery, and neonatal complications, are well documented. Yet the coverage system often treats gestational diabetes as lower priority for CGM access than other forms of diabetes, even though the stakes of uncontrolled blood sugar during pregnancy are arguably higher.

If you have gestational diabetes and want a Dexcom CGM, your options depend on your insurance. Some private plans will cover it, especially with a strong letter of medical necessity from your OB-GYN or maternal-fetal medicine specialist. If you’re on Medicaid, check whether your state is one of the few that covers CGM for gestational diabetes. If not, the Dexcom Stelo’s over-the-counter availability offers a self-pay option, though you should discuss with your provider whether the Stelo’s feature set is appropriate for your specific pregnancy needs, since gestational diabetes management sometimes requires the tighter monitoring capabilities of a prescription device.

Understanding the Real Cost Over Time

Thinking about the cost of a Dexcom CGM means looking beyond the sticker price of a single sensor. Each Dexcom G7 sensor lasts 10 days, so you’ll go through roughly three sensors per month. At full retail price without insurance, that adds up quickly over a year.

Health economic analyses have generally found that CGM is cost-effective compared to traditional fingerstick monitoring for people with type 1 diabetes, meaning the upfront costs are offset by fewer complications and hospitalizations over a patient’s lifetime. One Canadian analysis of an earlier Dexcom model found a cost-effectiveness ratio that health economists would consider a reasonable value for a medical intervention.⁹ A French analysis of the Dexcom G6 in type 1 diabetes reached a similar conclusion, with CGM adding quality-adjusted life years over a lifetime despite higher direct costs.¹⁰

These analyses influence whether insurers decide to cover CGMs and at what level. When the math shows that covering a device now prevents expensive emergency room visits and hospitalizations later, coverage tends to expand. The evidence on cost-effectiveness for type 2 diabetes is still building, and as it matures, it will likely play a role in loosening the restrictions that currently shut out many people.

For someone paying out of pocket right now, the practical question is simpler: can you afford the monthly cost, and is the benefit worth it? If you’re already spending money on frequent fingerstick testing supplies, the incremental cost of switching to CGM may be smaller than the retail price suggests, since you’ll largely eliminate the expense of test strips and lancets. And if the Dexcom Stelo’s lower price point fits your needs, the over-the-counter option brings the monthly cost down to a level that competes with what many people spend on basic fingerstick supplies alone.